Premium
A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study
Author(s) -
Bauer Madeline,
Reaman Gregory H.,
Hank Jacquelyn A.,
Cairo Mitchell S.,
Anderson Peter,
Blazar Bruce R.,
Frierdich Sharon,
Sondel Paul M.
Publication year - 1995
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19950615)75:12<2959::aid-cncr2820751225>3.0.co;2-r
Subject(s) - medicine , renal cell carcinoma , neuroblastoma , melanoma , lymphoma , oncology , refractory (planetary science) , transplantation , sarcoma , gastroenterology , cancer research , pathology , physics , astrobiology , genetics , biology , cell culture
Background. Recombinant human Interleukin‐2 (IL‐2) has been effective at inducing measurable antitumor responses in adults with renal cell carcinoma and melanoma. It also is being tested as adjuvant therapy for patients with acute myeloid leukemia after autologous bone marrow transplantation. Methods. The authors tested IL‐2 in a pediatric Phase II trial using a regimen that has antitumor effects in adults and was proven to be tolerated acceptably in a prior Phase I pediatric trial. Thirty‐eight patients were entered into this study of whom 36 received IL–2 and were evaluable (20 with sarcoma, 9 with neuroblastoma, 5.